Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Keita Nakamori, M.E.

Concepts (53)

Concepts are derived automatically from a person's publications.
The timeline below shows the dates (blue tick marks) of publications associated with Keita Nakamori's top concepts. The average publication date for each concept is shown as a red circle, illustrating changes in the primary topics that Keita Nakamori has written about over time.
Cisplatin, 2 publications between 2022 and 2023, average publication date November 2022. Carcinoma, Transitional Cell, 4 publications between 2022 and 2023, average publication date February 2023. Urinary Bladder Neoplasms, 8 publications between 2022 and 2023, average publication date March 2023. Lymphocytes, 3 publications between 2022 and 2023, average publication date March 2023. Neutrophils, 3 publications between 2022 and 2023, average publication date March 2023. Urologic Neoplasms, 2 publications between 2022 and 2023, average publication date April 2023. Organ Transplantation, 1 publications between 2023 and 2023, average publication date August 2023. Kidney Transplantation, 2 publications between 2023 and 2024, average publication date September 2023. Ureteral Neoplasms, 1 publications between 2023 and 2023, average publication date November 2023. Radiation Injuries, 1 publications between 2023 and 2023, average publication date December 2023. Urinary Bladder, 1 publications between 2023 and 2023, average publication date December 2023. Life Style, 1 publications between 2024 and 2024, average publication date February 2024. Living Donors, 1 publications between 2024 and 2024, average publication date February 2024.

To see the data from this visualization as text, click here.
Nakamori's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (53)
Explore
_
Co-Authors (3)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.